THE ARISING · DAILY EDITION
The Arising — October 29, 2026
Download the PDF ↓Longevity & Healthspan
Lilly's Triple-Hormone Drug Retatrutide Beat Ozempic on Blood Sugar and Weight at Its Top Dose
An experimental drug that acts on three hormone signals produced average weight loss of 20% to 21% in a head-to-head diabetes trial. Ozempic produced 9%. The drug, retatrutide, also led to more people stopping treatment because of side effects.
GLP-1 medicines →Probiotic Lowered Alzheimer's Blood Marker in Six-Month Placebo-Controlled Trial
Older adults with early memory and thinking problems who took a multistrain probiotic for 24 weeks had lower blood levels of an Alzheimer's-linked protein than those who took a placebo, according to a new trial in the Journal of Alzheimer's Disease.
Brain health →First Parkinson's Patient Dosed With Drug Designed to Clear Damaged Mitochondria
A drug built to help brain cells clear out their damaged power units has now been given to its first person with Parkinson's disease, but the trial is not designed to show whether it helps.
Brain health →Vessel-Function Test Before Stenting Did Not Predict Renarrowing in 91 Patients
A quick, non-invasive test of blood vessel function has been linked to heart risk, so it is fair to ask whether it can also show which stented arteries will narrow again. In a new study of 91 patients, a reading taken before the stent was placed did not independently tell much about how much the artery later narrowed.
Longevity in daily life →Researchers Argue Age-Related Muscle Loss Is a Nervous System Problem Too
Drugs that build muscle have often failed to make older people move better, and a group of researchers now says the reason may be that muscle was never the whole story.
Strength and function →Heart Mitochondria Burn Lactate Directly as Backup Fuel, Mouse Study Finds
The heart can burn lactate, a molecule often treated as a by-product of metabolism, by taking it straight into its energy-making compartments. That is the conclusion of a new study in Nature, and it challenges a standard picture of how heart cells use fuel.
Strength and function →Coaching Program Linked to Greater Weight Loss in GLP-1 Users
Weight loss on a GLP-1 drug is not only fat loss, and a new study asks whether exercise coaching can change what the body gives up. The fat and muscle figures below come from press coverage, and the study was run by the programme's own provider.
GLP-1 medicines →Nurse-Led Coaching Trial Trimmed Dementia Risk Scores, but Not Cognition
A year of nurse-led coaching moved a questionnaire-based dementia risk score in a better direction for middle-aged Australians, but thinking skills, quality of life and heart risk did not differ from usual care, according to News-Medical's report of a new trial.
Brain health →Elinzanetant Halved Hot Flashes in Two-Thirds of US Trial Participants
About two in three US women who took the non-hormonal drug elinzanetant had at least half of their moderate-to-severe hot flashes disappear within three months, according to Contemporary OB/GYN's report of a new analysis. About four in ten women on placebo had the same result.
Reading medical evidence →New Lipid Carriers Steer mRNA Cancer Vaccines to the Spleen in Mice
Chinese chemists built 40 retinoic-acid-based lipids and found one that raised spleen expression about 15-fold over a standard spleentargeting formula. The mouse results are promising; human data do not exist yet.
Reading medical evidence →